Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22

Articles

254527 items
12:00 AM, May 02, 1994  |  BioCentury | Tools & Techniques

Different routes to human monoclonals in mice

In their ongoing race to develop human antibodies, Cell Genesys Inc. (CEGE) and GenPharm International reported simultaneously that they have produced human monoclonals in mice. CEGE reported in Nature Genetics that it used gene targeting to...
12:00 AM, May 02, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Lenoxin data

The New York company announced results of a Phase III trial in 740 patients, showing that itching and swelling due to GPC resolved almost completely in three weeks, as compared to months with available treatments...
12:00 AM, May 02, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Incyte Pharmaceuticals Inc. regulatory update

IPI (Palo Alto) this week is to receive U.S. Patent No. 5,308,834 covering the use of bactericidal/permeability-increasing protein, its lead biotherapeutic, and fragments thereof, in the treatment of endotoxemia. Incyte Pharmaceuticals Inc. (IPI)   ...
12:00 AM, May 02, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Recombinant human bactericidal/permeability-increasing protein data

IPI published mouse data in Critical Care Medicine showing that the binding affinity of BPI for endotoxin is greater than the binding affinities of Centocor Inc.'s HA-1A monoclonal antibody and Xoma Corp.'s E5 MAb....
12:00 AM, May 02, 1994  |  BC Week In Review | Company News  |  Deals

Pharmos deal

PARS (New York) signed a letter of intent with Bausch & Lomb Pharmaceuticals Inc. under which Bausch & Lomb will market Lenoxin (lotepredol etabonate), which is in Phase III trials for giant papillary and seasonal...
12:00 AM, May 02, 1994  |  BC Week In Review | Company News  |  Deals

Genzyme Transgenics deal

Genzyme Transgenics Corp. (GZTC)   The Framingham, Mass., company and its Japanese joint venture partner, Sumitomo Metal Industries Ltd., committed up to $7.7 million in additional capital to fund development of transgenically produced proteins. SMI agreed...
12:00 AM, May 02, 1994  |  BC Week In Review | Company News  |  Sales & Marketing

DDI sales and marketing update

The Mountain View, Calif., company received a $1.5 million order from Sterling Winthrop for DDIX's bulk bovine superoxide dismutase (bSOD). Sterling uses bSOD as an active ingredient in a drug to treat severe closed head...
12:00 AM, May 02, 1994  |  BC Week In Review | Company News  |  Deals

Neurex deal

Medronic will invest an additional $14 million through a combination of equity and milestones over the next three years. An IND will be filed by the end of this year for chronic neuropathic pain by...
12:00 AM, Apr 25, 1994  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Mycogen Corp. (MYCO) George Dahlman of Piper Jaffray said MYCO's first quarter earnings, at 55 cents on a fully diluted basis, were well above his expectation of 15 cents. Although revenues were flat, the agbio...
12:00 AM, Apr 25, 1994  |  BioCentury | Politics, Policy & Law

Opposition to Bayh-Dole controls

WASHINGTON - A battle is brewing in Congress over attempts to impose price controls and competitive bidding on licensing agreements between businesses and federally funded research institutions. The "Federal Research Product Commercialization Act" (H.R. 1334),...

Pages